T cell therapy shows promise in treating aggressive brain cancer
A new phase 1 clinical trial has found that an emerging immunotherapy is promising for treating recurrent glioblastoma, a highly aggressive and fatal brain cancer. Chimeric antigen receptor T (CAR-T) cell therapy is a form of immunotherapy that modifies an individual's own T cells (a type of immune cell) so they are better able to recognize and destroy cancer cells. The new clinical trial, the…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
